Keyphrases
Adenocarcinoma
9%
Adverse Events
9%
Cancer Cells
16%
Cancer Patients
11%
Chemotherapy
20%
Cisplatin
7%
Clinical Trials
8%
Confidence Interval
17%
DNA Damage
8%
Durvalumab
15%
Early-stage Lung Cancer
8%
EGFR mutation
11%
Epidermal Growth Factor Receptor
9%
Erlotinib
7%
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
11%
Hazard Ratio
11%
Immune Checkpoint Inhibitors
24%
Immunohistochemistry
8%
In Cancer
10%
Interferon-α (IFN-α)
9%
Israel
10%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
55%
Lung Cancer
40%
Lung Cancer Patients
18%
Median Overall Survival
11%
Median Progression-free Survival
6%
Melanoma Patients
6%
Metastatic Disease
8%
Monotherapy
6%
Multivariate Analysis
7%
Nivolumab
12%
Non-small Cell Lung Cancer (NSCLC)
75%
Non-small Cell Lung Cancer Patients
26%
Objective Response Rate
9%
Osimertinib
9%
Overall Survival
39%
Pembrolizumab
17%
Phase I Study
6%
Phase II Trial
6%
Platinum-based Chemotherapy
12%
Predictive Biomarker
8%
Programmed Death-ligand 1 (PD-L1)
9%
Progression-free Survival
13%
Real-life Cohort
6%
Retrospective Analysis
9%
Small Cell Lung Cancer
15%
Stromal Cells
7%
Tumor
27%
Tumor Cells
10%
Tyrosine Kinase Inhibitor
11%
Medicine and Dentistry
Adenocarcinoma
14%
Adverse Event
11%
Angiogenesis
5%
Arm
5%
Biological Marker
10%
Biopsy
6%
Brain Metastasis
5%
Breast Cancer
6%
Cancer Cell
10%
Cell Invasion
6%
Chemoradiotherapy
17%
Cisplatin
7%
Clinical Trial
12%
Colorectal Cancer
6%
COVID-19
6%
Disease
17%
Durvalumab
15%
Electrocorticography
6%
Epidermal Growth Factor Receptor
35%
Erlotinib
6%
Exon
11%
Fibroblast
7%
Hazard Ratio
12%
Immune Checkpoint Inhibitor
21%
Immunohistochemistry
7%
Immunotherapy
16%
Interferon
6%
Liquid Biopsy
6%
Long Term Survival
6%
Lung Cancer
50%
Malignant Neoplasm
24%
Metastatic Carcinoma
13%
Neoplasm
37%
Nivolumab
12%
Nodular Melanoma
6%
Non Small Cell Lung Cancer
100%
Non-Small Cell Lung Cancer
14%
Osimertinib
9%
Overall Survival
37%
Pembrolizumab
10%
Programmed Death-Ligand 1
6%
Progression Free Survival
19%
Protein P53
7%
Radiation Therapy
13%
Retrospective Study
5%
Small Cell Lung Cancer
17%
Smoking
7%
Surgery
5%
Tumor Cell
11%
Tyrosine-Kinase Inhibitor
16%
Pharmacology, Toxicology and Pharmaceutical Science
Adenocarcinoma
9%
Adverse Event
15%
Biological Marker
10%
Brain Metastasis
5%
Carboplatin
5%
Cediranib
6%
Chemoradiation Therapy
15%
Chemotherapy
36%
Cisplatin
10%
Clinical Trial
9%
Colorectal Cancer
9%
Coronavirinae
6%
Crizotinib
5%
Disease
21%
Durvalumab
18%
Epidermal Growth Factor Receptor
32%
Erlotinib
9%
Immune Checkpoint Inhibitor
15%
Immunotherapy
12%
Interferon
6%
Lactate Dehydrogenase
6%
Long Term Survival
6%
Lung Cancer
49%
Malignant Neoplasm
34%
Metastasis
7%
microRNA
5%
Neoplasm
34%
Nivolumab
9%
Non Small Cell Lung Cancer
83%
Osimertinib
12%
Overall Survival
40%
Pembrolizumab
17%
Progression Free Survival
24%
Protein P53
15%
Protein Tyrosine Kinase Inhibitor
18%
Recurrent Disease
6%
Small Cell Lung Cancer
17%
Veliparib
6%
